| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5894d694d4a784d601f503d79e518f2d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-577 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-247 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2018-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ea2f829a0e7f2881ad0c7bad9dd1b0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfb2e0f58d1f465f7faf0b0fa0c6a6e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bf6bc327151721c102504f898a10749 |
| publicationDate |
2019-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019028367-A1 |
| titleOfInvention |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| abstract |
The present invention provides methods of treating, preventing or reducing the severity of active eosinophilic esophagitis. In some embodiments, the present invention provides methods for increasing esophageal distention. The methods of the present invention include administering to a subject in need of a pharmaceutical composition comprising an interleukin-4 interleukin 13 (IL-4 / IL-13) inhibitor such as a anti-IL-4R antibody. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020135471-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021237110-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214621-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021011614-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779604-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11773175-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753479-B2 |
| priorityDate |
2017-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |